AppLovin (NasdaqGS:APP) recently reported strong first-quarter results with significant sales and net income increases, alongside issuing positive guidance for the second quarter, which seems to align ...

Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. The market awaits NeoGenomics's ...

Q1 2025 Management View CEO Gerard Michel highlighted the combined Q1 2025 revenue of $19.8 million, with HEPZATO ...

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) will be featured at the 2025 ...

Q1 2025 Earnings Call Transcript May 6, 2025 Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $-0.03, ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

Analysts have recently evaluated Veracyte and provided 12-month price targets. The average target is $44.71, accompanied by a ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Edna Bonhomme, author of "A History of the World in Six Plagues," details how pandemics are about more than viruses ...

Learn more about whether Option Care Health, Inc. or Premier, Inc. is a better investment based on AAII's A+ Investor grades, ...

Advances in AI, genomics, and liquid biopsy are reshaping cancer care, but systemic gaps persist in access and funding, ...

Data on the efficacy of radical prostatectomy in managing clinically node-positive prostate cancer have been limited.